Skip to main content

Table 1 Demographic characteristics of cancer patients in Korea in 2006, NHIS-NSC

From: Impact of comorbidity assessment methods to predict non-cancer mortality risk in cancer patients: a retrospective observational study using the National Health Insurance Service claims-based data in Korea

 

Total (n = 2979)

Male (n = 1514)

Female (n = 1465)

n

%

n

%

n

%

Age, mean (SD), median

57.4 (15.4)

59.0

59.1 (15.0)

62.0

55.5 (15.6)

55.0

Survival time in years, mean (SD), median

7.1 (3.4)

9.2

6.6 (2.1)

9.0

7.8 (3.1)

9.3

Sex

 Male

1514

50.8

    

 Female

1465

49.2

    

Cause of Death

 Cancer death

686

23.0

434

28.7

252

17.2

 Other cancer death

135

4.5

86

5.7

49

3.3

 Non-cancer death

238

8.0

150

9.9

88

6.0

 Alive

1920

64.5

844

55.7

1076

73.4

Cancer type (ICD-10)

 Stomach (C16)

491

16.5

328

21.7

163

11.01

 Colon and rectum (C18-C20)

403

13.5

232

15.3

171

11.7

 Liver (C22)

258

8.7

183

12.1

75

5.1

 Gallbladder (C23-C24)

60

2.0

25

1.7

35

2.4

 Pancreas (C25)

58

1.9

29

1.9

29

2.0

 Lung (C33-C34)

232

7.8

157

10.4

75

5.1

 Bladder (C67)

71

2.4

61

4.0

10

.7

 Thyroid (C73)

295

9.9

54

3.6

241

16.5

 Non-Hodgkin lymphoma (C82-C85, C96)

57

1.9

31

2.0

26

1.8

 Genital organs a)

592

19.9

133

8.8

459

31.3

 Other Cancer b)

462

15.5

281

18.6

181

12.4

  1. SD Standard deviation, NHIS-NSC National Health Insurance Service-National Sample Cohort
  2. a) Cancer sites are masked and grouped: Breast (C50), Vulva (C51), Vagina (C52), Cervix uteri (C53), Corpus uteri (C54), Uterus unspecified (C55), Ovary (C56), other female genital organs (C57), Placenta (C58) in females and Penis (C60), Prostate (C61), Testis (C62), and other male genital organs (C63) in males
  3. b) “Other cancers” include Lip, oral cavity, and pharynx (C00-C14), Esophagus (C15), Larynx (C32), Kidney (C64), Brain and central nervous system (CNS) (C70-C72), Hodgkin lymphoma (C81), Multiple myeloma (C90), Leukemia (C91-C95), and Other malignant neoplasms (Remainder C00–C97)